---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000040"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:35:28.244696+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caribou Q1 net loss $40M; cuts 32% workforce, extends cash runway into H2 2027

## Summary
- Cash, equivalents & securities $212.5M as of Mar 31, 2025 (down from $249.4M at Dec 31, 2024).
- Net loss $40.0M vs $41.2M YoY; R&D expenses $35.5M (up from $33.8M) and G&A $9.7M (down from $14.6M).
- Discontinued CB-010 lupus trial, CB-012 AML trial, and preclinical work; workforce reduced ~32% with $2.5–3.5M cash costs.
- CB-010 (2L LBCL) and CB-011 (multiple myeloma) Phase 1 data expected in H2 2025 with FDA interaction for potential pivotal trial.
- Licensing revenue flat at $2.4M for the quarter.

## SEC filing metadata
- accession: 0001619856-25-000040
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/0001619856-25-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/crbu-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000040
- JSON: https://secwatch.observer/filing/0001619856-25-000040.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.